RICHMOND, Va.--(BUSINESS WIRE)--March 28, 2003--Insmed, Incorporated (NASDAQ/NMS: INSM - News), a biopharmaceutical company engaged in the development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs, today announced that it has retained Investor Relations International (IRI) to expand the Company's strategic investor relations program.
"We are pleased to have Investor Relations International working with us to increase the investment community's interest in Insmed Incorporated," said Dr. Geoffrey Allan, Chairman and Chief Executive Officer of Insmed Incorporated. "This is an exciting time for our company and we believe with the help of Investor Relations International we will be able to more broadly and effectively communicate our story to the investment community."
Haris Tajyar, Managing Partner of Investor Relations International, said, "We are looking forward to communicating Insmed's investment story to beyond its existing shareholder base and the biotech investment community. We believe the company should be of particular interest to value investors given that the company is currently trading below cash per share and, from our perspective, is significantly undervalued when considering the vast potential of its blockbuster drugs, recent financial improvements and strong balance sheet," concluded Mr. Tajyar.
To be added to Insmed's investor e-mail and/or fax lists, please contact Baxter Phillips of Insmed at bphillips@insmed.com.
About Investor Relations International, Inc.
Investor Relations International, Inc. (IRI) www.irintl.com is a full-service investor relations firm serving clients from New York to China. The principals of IRI have received top industry awards for their investor relations programs for a number of high-profile companies, including, but not limited to, Starwood Hotels & Resorts Worldwide (NYSE: HOT - News), ValueVision Media (Nasdaq: VVTV - News), Taro Pharmaceuticals (Nasdaq: TARO - News) and Qiao Xing Universal Telephone (Nasdaq: XING - News). The firm's principals have executed effective investor relations programs for dozens of public companies, ranging from emerging micro-cap companies to multinational corporations with market capitalizations in excess of $15 billion. For further information on IRI, please visit the firm's Website at www.irintl.com. |
